Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Yale Univeristy

Neither a doctor nor a teaching hospital

Research payments

$782,708

56 payments

Through program year 2025, Yale Univeristy is reported as receiving $782,708 in research payments, across 56 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $95,943 4
2024 Research $45,479 5
2023 Research $29,318 5
2022 Research $709 2
2021 Research $273,606 26
2020 Research $337,655 14

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $550,203 34 payments
  2. Sanofi US Services Inc. $95,943 4 payments
  3. Genzyme Corporation $74,797 10 payments
  4. AstraZeneca UK Limited $55,520 2 payments
  5. Acerta Pharma LLC $5,436 2 payments
  6. Dexcom, Inc. $709 2 payments
  7. AstraZeneca AB $102 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. Temozolomide and Olaparib for O6-Methyguanine DNA Methyltransferase Promoter Hypermethylated Colorectal Cancer $209,509 1 payment
  2. A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, ER positive, HER2 negative breast cancer (DARE) $203,600 1 payment
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis $95,943 4 payments
  4. A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (GD3) Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ERT) $74,797 10 payments
  5. Effects of Concurrent Chemoradiotherapy on the immune Microenvironment in Stage III NSCLC $50,700 1 payment
  6. iMED Oncology project- Sarah Cannon Research Institute Agreemet $48,641 1 payment
  7. A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD) $25,816 2 payments
  8. urvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) $13,506 2 payments
  9. An Open Label, Randomised, Multi Drug, Biomarker Directed, Multi Centre, Multi arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer MIBC who have progressed on prior treatment BISCAY $12,100 2 payments
  10. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $8,430 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record